Insight

Kinetic Profiling

Sep 6, 2024, 09:54

Kinetic Profiling of RAS Mutations With Circulating Tumor DNA Suggests the Loss of RAS Mutations in Neo-RAS-Wildtype Metastatic Colorectal Cancer Is Transient

JCO Precision Oncology made the following post on X:

“Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo-RAS-Wildtype Metastatic Colorectal Cancer Is Transient.”

Authors: Florence T.H. Wu, James T. Topham, Chris J. O’Callaghan, Harriet Feilotter, Hagen F. Kennecke, Leylah Drusbosky, Daniel J. Renouf, Derek J. Jonker, Dongsheng Tu, Eric X. Chen, Jonathan M. Loree.

Source: JCO Precision Oncology/X

Canadian Cancer Trials Group CO.26 Trial cancer Chris J. O'Callaghan Circulating tumor DNA Daniel J Renouf Derek J. Jonker Dongsheng Tu Eric X. Chen Florence T.H. Wu Hagen F.Kennecke Harriet Feilotter James T. Topham Jonathan M. Loree Leylah Drusbosky Metastatic colorectal cancer OncoDaily Oncology RAS mutations

100 Oncologists, One Community: Reflections from the First ESO College Convention

Gevorg Tamamyan: "Fertility News" is on the Way

JCO on a Jamaican Beach: The Journey of Joyson Karakunnel

Patrick Soon-Shiong: NK cells matter!

Anas Younes Has Been Appointed Chief Medical Officer at AstraZeneca